Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2014

01-12-2014 | Research Article

Association of TP53 PIN3 polymorphism with breast cancer in Moroccan population

Authors: Chaymaa Marouf, Amal Tazzite, Brehima Diakité, Hassan Jouhadi, Abdellatif Benider, Sellama Nadifi

Published in: Tumor Biology | Issue 12/2014

Login to get access

Abstract

TP53 is a tumor suppressor gene involved in cell cycle progression control, DNA damage repair, genomic stability, and apoptosis. Some polymorphisms in this gene have been associated with the development of a number of cancers including breast carcinoma. PIN3 Ins16bp polymorphism has been widely studied in different populations for an association with breast cancer risk. In most case-control studies, a duplicated allele has been more frequent in cases rather than controls but there are also inconsistent results. The present study aimed to assess the association of PIN3 Ins16bp polymorphism of p53 with breast cancer risk in Moroccan population. This case-control study was performed on 105 female patients with confirmed breast cancer and 114 healthy controls. The genotype frequency was 69.5 % (A1A1), 26.7 % (A1A2), and 3.8 % (A2A2) in patients and 68.4 % (A1A1), 24.6 % (A1A2), and 7 % (A2A2) in controls. No statistically significant association was observed between PIN3 Ins16bp polymorphism and breast cancer risk with odds ratio of 1.07 (confidence interval (CI) = 0.58–1.97, p = 0.83) for the heterozygous A1A2 and 0.53 (CI = 0.15–1.85, p = 0.32) for mutated homozygous A2A2.According to our preliminary genetic analysis, PIN3 Ins16pb polymorphism could not be assessed as a marker of risk factor for predisposition to breast cancer in Moroccan population. However, a high frequency of A2 allele (19.3 %) in our population suggested that PIN3 Ins16pb polymorphism may be a valuable marker for study in other cancers with larger groups.
Literature
1.
Bonadona V, Lasset C. Inherited predisposition to breast cancer: after the BRCA1 and BRCA2 genes, what next? Bull Cancer. 2003;90:587–4.PubMed
2.
Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–10.PubMed
3.
Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006;12:909–23.
4.
Bourdon A, Minai L, Serre V, Jais JP, Sarzi E, Aubert S, et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet. 2007;39:776–80.PubMed
5.
Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8:275–83.PubMed
6.
Van der Groep P, Van der Wall E, Van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol. 2011;34:71–88.
7.
Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49–53.PubMed
8.
Farnebo M, Bykov VJ, Wiman KG. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun. 2010;396:85–9.PubMed
9.
Pouladi N, Kouhsari SM, Feizi MH, Gavgani RR, Azarfam P. Overlapping region of p53/wrap53 transcripts: mutational analysis and sequence similarity with microRNA-4732-5p. Asian Pac J Cancer Prev. 2013;14:3503–7.PubMed
10.
Chompret A, Brugières L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000;82:1932–7.PubMedPubMedCentral
11.
Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95–107.PubMed
12.
Guleria K, Sharma S, Manjari M, Singh Uppal M, Rajan Singh N, Sambyal V. P.R72P, PIN3 Ins16bp polymorphisms of TP53 and CCR5Δ32 in north Indian breast cancer patients. Asian Pac J Cancer Prev. 2012;13:3305–11.PubMed
13.
Roy AG, Sarkar B, Roy R, Rao V, Bandyopadhyay A. Absence of p53 gene mutations in exons 5–7 among breast cancer patients of Bengalee Hindu caste females, West Bengal India. Asian Pac J Cancer Prev. 2012;13:4477–9.PubMed
14.
Vijayaraman KP, Veluchamy M, Murugesan P, Shanmugiah KP, Kasi PD. p53 exon 4 (codon 72) polymorphism and exon 7 (codon 249) mutation in breast cancer patients in southern region (Madurai) of Tamil Nadu. Asian Pac J Cancer Prev. 2012;13:511–6.PubMed
15.
Lehman TA, Haffty BG, Carbone CJ, Bishop LR, Gumbs AA, Krishnan S, et al. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res. 2000;60:1062–9.PubMed
16.
Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutiérrez-Enriquez S, et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene. 2004;23:1954–6.PubMed
17.
Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, et al. p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst. 2002;94:681–90.PubMed
18.
Runnebaum IB, Tong XW, König R, Zhao H, Körner K, Atkinson EN, et al. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet. 1995;345:994.PubMed
19.
Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, et al. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer. 2008;8:32.PubMedPubMedCentral
20.
Malik MA, Sharma K, Goel S, Zargar SA, Mittal B. Association of TP53 intron 3, 16bp duplication polymorphism with esophageal and gastric cancer susceptibility in Kashmir Valley. Oncol Res. 2011;19:165–9.PubMed
21.
Hu Z, Li X, Qu X, He Y, Ring BZ, Song E, et al. Intron 3 16bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis. 2010;31:643–7.PubMed
22.
He XF, Su J, Zhang Y, Huang X, Liu Y, Ding DP, et al. Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res Treat. 2011;130:517–29.PubMed
23.
Sagne C, Marcel V, Amadou A, Hainaut P, Olivier M, Hall J. A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. Cell Death Dis. 2013;4:492.
24.
Wu D, Zhang Z, Chu H, Xu M, Xue Y, Zhu H, et al. Intron 3 Sixteen base pairs duplication polymorphism of p53 contributes to breast cancer susceptibility: evidence from meta-analysis. PLoS One. 2013;8:61662.
25.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMed
26.
Bouchbika Z, Haddad H, Benchakroun N, Eddakaoui H, Kotbi S, Megrini A, et al. Cancer incidence in Morocco: report from Casablanca registry 2005-2007. Pan Afr Med J. 2013;16:31.PubMedPubMedCentral
27.
Tazi MA, Er-Raki A, Benjaafar N. Cancer incidence in Rabat, Morocco: 2006-2008. Ecancer. 2013;7:338.
28.
Hamdi Cherif M, Zaidi Z, Abdellouche D, Hamdi S, Lakhdari N, Djema BA. Registre du cancer de Sétif (Algérie): incidence, tendance et survie, 1986–2005. J Afr Cancer. 2010;2:245–58.
29.
Ben Abdallah M, Zehani S, Maalej M, Hsairi M, Hechiche M, Ben Romdhane K, et al. Cancer du sein en Tunisie: caractéristiques épidémiologiques et tendance évolutive de l'incidence. Tunis Med. 2009;87:417–25.PubMed
30.
El Mistiri M, Pirani M, El Sahli N, El Mangoush M, Attia A, Shembesh R, et al. Cancer profile in eastern Libya: incidence and mortality in the year 2004. Ann Oncol. 2010;21:1924–6.PubMed
31.
32.
Botha JL, Bray F, Sankila R, Parkin DM. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer. 2003;39:1718–29.PubMed
33.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMed
34.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.PubMedPubMedCentral
35.
Brankovic-Magic MV, Jankovic RN, Dobricic JD, Borojevic ND, Magic ZM, Radulovic SS. TP53 mutations in breast cancer: association with ductal histology and early relapse of disease. Int J Biol Markers. 2008;23:147–53.PubMed
36.
Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 1993;362:849–52.PubMed
37.
Kulesz-Martin MF, Lisafeld B, Huang H, Kisiel ND, Lee L. Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells. Mol Cell Biol. 1994;14:1698–708.PubMedPubMedCentral
38.
Puisieux A, Lim S, Groopman J, Ozturk M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res. 1991;51:6185–9.PubMed
39.
Pavletich NP, Chambers KA, Pabo CO. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 1993;7:2556–64.PubMed
40.
Chang F, Syrjänen S, Kurvinen K, Syrjänen K. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Am J Gastroenterol. 1993;88:174–86.PubMed
41.
Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993;329:1318–27.PubMed
42.
Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang-Claude J. Intron 3 16bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics. 2002;12:269–72.PubMed
43.
Bisof V et al. TP53 gene polymorphisms and breast cancer in Croatian women: a pilot study. Eur J Gynaecol Oncol. 2010;31:539–44.PubMed
44.
Faghani M, Ghasemi FM, Nikhbakht M, Salehi M. TP53 PIN3 polymorphism associated with breast cancer risk in Iranian women. Indian J Cancer. 2011;48:298–302.PubMed
45.
Peller S, Kopilova Y, Slutzki S, Halevy A, Kvitko K, Rotter V. A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol. 1995;14:983–90.PubMed
46.
Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, et al. p53 haplotype determination in breast cancer. Cancer Epidemiol Biomark Prev. 1997;6:105–12.
47.
Suspitsin EN, Buslov KG, Grigoriev MY, Ishutkina JG, Ulibina JM, Gorodinskaya VM, et al. Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer. 2003;103:431–3.PubMed
48.
Fiszer-Maliszewska Ł, Kazanowska B, Kuśnierczyk P, Mańczak M, Niepiekło W, Pochroń-Zeman B, et al. Is p53 intronic variant G13964C associated with predisposition to cancer? J Appl Genet. 2004;44:547–52.
49.
Buyru N, Altinisik J, Demokan S, Dalay N. p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect Prev. 2007;31:207–13.PubMed
50.
De Vecchi G, Verderio P, Pizzamiglio S, Manoukian S, Bernard L, Pensotti V, et al. The p53 Arg72Pro and Ins16 bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. Cancer Detect Prev. 2008;32:140–3.PubMed
51.
Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D, et al. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer. 2008;8:96.PubMedPubMedCentral
52.
Trifa F, Karray-Chouayekh S, Mabrouk I, Baccouche S, Khabir A, Sellami-Boudawara T, et al. Haplotype analysis of p53 polymorphisms: Arg72Pro, Ins16 bp and G13964C in Tunisian patients with familial or sporadic breast cancer. Cancer Epidemiol. 2010;34:184–8.PubMed
53.
Pouladi N, Kouhsari SM, Feizi MH, Dehghan R, Azarfam P, Farajzadeh D. Lack of association of intron 3 16bp polymorphism of TP53 with breast cancer among Iranian-Azeri patients. Asian Pac J Cancer Prev. 2014;15:2631–4.PubMed
54.
Akkiprik M, Sonmez O, Gulluoglu BM, Caglar HB, Kaya H, Demirkalem P, et al. Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer. Pathol Onco Res. 2009;15:359–68.
55.
Osorio A, Pollán M, Pita G, Schmutzler RK, Versmold B, Engel C, et al. CIMBA. An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2008;99:974–7.PubMedPubMedCentral
56.
Alawadi S, Ghabreau L, Alsaleh M, Abdulaziz Z, Rafeek M, Akil N, et al. P53 gene polymorphisms and breast cancer risk in Arab women. Med Oncol. 2011;28:709–15.PubMed
57.
Khaliq S, Hameed A, Khaliq T, Ayub Q, Qamar R, Mohyuddin A, et al. P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet Test. 2000;4:23–9.PubMed
58.
Mahasneh AA, Abdel-Hafiz SS. Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. Saudi Med J. 2004;25:1568–73.PubMed
59.
Wang-Gohrke S, Rebbeck TR, Besenfelder W, Kreienberg R, Runnebaum IB. p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res. 1998;18:2095–9.PubMed
60.
Olden K, Freudenberg N, Dowd J, Shields AE. Discovering how environmental exposures alter genes could lead to new treatments for chronic illnesses. Health Aff (Millwood). 2011;30:833–41.
Metadata
Title
Association of TP53 PIN3 polymorphism with breast cancer in Moroccan population
Authors
Chaymaa Marouf
Amal Tazzite
Brehima Diakité
Hassan Jouhadi
Abdellatif Benider
Sellama Nadifi
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2556-y

Other articles of this Issue 12/2014

Tumor Biology 12/2014 Go to the issue

Research Article

miR-141 suppresses the growth and metastasis of HCC cells by targeting E2F3

Research Article

RETRACTED ARTICLE: Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73 in hepatocellular carcinomas with low AFP levels

Research Article

Effects of interleukin-18 promoter (C607A and G137C) gene polymorphisms and their association with oral squamous cell carcinoma (OSCC) in northern India

Research Article

RETRACTED ARTICLE: Improving the diagnosis, treatment, and biology patterns of feline mammary intraepithelial lesions: a potential model for human breast masses with evidence from epidemiologic and cytohistopathologic studies

Research Article

The ALDH7A1 genetic polymorphisms contribute to development of esophageal squamous cell carcinoma

Research Article

MiR99a modulates MMP7 and MMP13 to regulate invasiveness of Kaposi’s sarcoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits